Histocell successfully completes phase I of clinical trial for the treatment of respiratory distress caused by COVID-19

Osakidetza and the Basque bio-pharmaceutical company, Histocell (member of the Basque Health Cluster) have successfully completed the first phase of the clinical trial for the drug HC016 for the treatment of respiratory distress caused by COVID-19. The trial is for the cell therapy drug HC016, developed by Histocell, taking place in collaboration with the Biocruces…